PTPRC and Stroke: The other study targeted the late stroke phase (i.e., days 5 and 14 after stroke), and characterized immune cells with high CD45 expression (CD45hi) in the brain, which precluded analysis of most microglia with low CD45 expression (CD45low) [13].